Gain Therapeutics (NASDAQ:GANX) Given “Buy” Rating at BTIG Research

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating restated by BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They presently have a $5.00 target price on the stock. BTIG Research’s price target suggests a potential upside of 146.91% from the company’s current price.

Several other equities research analysts also recently commented on GANX. Roth Mkm reaffirmed a “buy” rating on shares of Gain Therapeutics in a research note on Tuesday, May 12th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Weiss Ratings cut shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Gain Therapeutics Trading Up 2.3%

Shares of Gain Therapeutics stock traded up $0.04 during trading on Tuesday, hitting $2.02. 3,454,219 shares of the company were exchanged, compared to its average volume of 841,737. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a market capitalization of $86.37 million, a P/E ratio of -3.47 and a beta of 0.16. The firm’s fifty day moving average price is $1.82 and its 200 day moving average price is $2.17. Gain Therapeutics has a 1-year low of $1.41 and a 1-year high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.13). During the same quarter last year, the company earned ($0.16) earnings per share. As a group, sell-side analysts expect that Gain Therapeutics will post -0.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC increased its holdings in Gain Therapeutics by 33.7% during the 1st quarter. Apollon Wealth Management LLC now owns 26,500 shares of the company’s stock worth $51,000 after purchasing an additional 6,675 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Gain Therapeutics by 2.9% in the second quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares in the last quarter. Sprott Inc. bought a new stake in shares of Gain Therapeutics in the fourth quarter valued at about $39,000. Commonwealth Equity Services LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth about $41,000. Finally, Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth about $45,000. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.